CX3CR1 identifies a potent effector CD8⁺ T cell subset associated with anti-PD-1 therapeutic efficacy in colorectal...

The therapeutic landscape for deficient mismatch repair (dMMR) colorectal cancer (CRC) has been fundamentally transformed by the introduction of immune checkpoint inhibitors (ICIs). Yet, a significant fraction of patients exhibits primary or acquired resistance, underscoring a critical unmet need to decode the heterogeneity of tumor-infiltrating CD8⁺T cells. Identifying the effector subsets that truly drive tumor control will be essential for refining patient stratification and optimizing therapeutic interventions.

By leveraging a multi-dimensional approach that combined single-cell RNA sequencing (scRNA-seq), multiplex immunohistochemistry (mIHC), extensive clinical data mining, and in vivo murine models, we comprehensively delineated the phenotypic profile, regulatory networks, and clinical relevance of intratumoral CX3CR1⁺CD8⁺T cells.

We uncovered a unique CX3CR1⁺CD8⁺ T cell subset exhibiting a Temra-like terminal effector phenotype characterized by potent cytotoxicity (GNLY, PRF1) and low exhaustion. Clinically, enrichment of this population emerged as a strong, independent predictor of improved overall survival in CRC. Mechanistically, effective anti-PD-1 therapy revitalizes anti-tumor immunity by specifically promoting the proliferation and maintaining the function of these CX3CR1⁺ effector cells within the tumor. SCENIC analysis further revealed that this differentiation pathway is orchestrated by ETS1, PRDM1 and STAT1 driven regulatory network, which is markedly induced following PD-1 inhibition to enhance metabolic fitness and cellular recruitment.

This study characterizes CX3CR1⁺CD8⁺T cells as a key effector subset predicting prognosis and immunotherapy response in colorectal cancer. These insights not only support their use as a clinically meaningful biomarker but also highlight the regulatory network orchestrated by ETS1 and PRDM1 as a promising avenue for overcoming immune resistance.